Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Alpine Immune Sciences’ $150 Million Common Stock Offering
Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the offering, and Latham & Watkins advised the underwriters. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the...
Boston Scientific’s $850 Million Acquisition of Relievant MedSystems
Faegre Drinker advised Boston Scientific, and Latham & Watkins advised Relievant MedSystems on the deal. Boston Scientific Corporation (NYSE: BSX) announced it has entered into a...
Gilead’s $2 Billion Senior Unsecured Notes Offering
Davis Polk advised Gilead, and Latham & Watkins advised the underwriters. Gilead Sciences, Inc. (Nasdaq: GILD) announced the pricing of senior unsecured notes in an aggregate...
Revolution Medicines’ Acquisition of EQRx
Latham & Watkins advises Revolution Medicines on the deal, and Goodwin Procter advises EQRx. Revolution Medicines, Inc. (Nasdaq: RVMD) and EQRx, Inc. (Nasdaq: EQRX) announced a definitive agreement...
Merck’s Acquisition of Prometheus Biosciences
Paul, Weiss, Rifkind, Wharton & Garrison represented Merck, Latham & Watkins represented Prometheus, Skadden represented the financial advisors on the deal. Prometheus Biosciences, Inc. have entered...
Sonoma Biotherapeutics’ Collaboration Agreement with Regeneron Pharmaceuticals
Latham & Watkins advised Sonoma Biotherapeutics on the transaction. Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a collaboration to apply their scientific and...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Mineralys Therapeutics’ $192 Million Initial Public Offering
Latham & Watkins advised Mineralys Therapeutics, and Shearman & Sterling advised the underwriters. Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the pricing of its upsized initial public...
Anima Biotech’s Collaboration with AbbVie
Latham & Watkins advised Anima in the transaction. AbbVie (NYSE: ABBV) and Anima Biotech (Anima) have announced a collaboration to discover and develop mRNA biology modulators...
Alphatec Spine’s $200 Million Growth Financing Facilities
Latham & Watkins LLP represented Alphatec in the transactions. Alphatec Holdings, Inc. (Nasdaq: ATEC), a medical technology company focusing on surgical treatment for spinal disorders has...
Geron Corporation’s $198 Million Upsized Public Offering
Cooley advised Geron, while Latham & Watkins represented the underwriters in the offering. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, has announced the pricing...